These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29247522)

  • 1. Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Mohanan E; Panetta JC; Lakshmi KM; Edison ES; Korula A; Na F; Abraham A; Viswabandya A; George B; Mathews V; Srivastava A; Balasubramanian P
    Clin Pharmacol Ther; 2018 Sep; 104(3):575-583. PubMed ID: 29247522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between exposure to treosulfan and its monoepoxytransformer - An insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation.
    Danielak D; Kasprzyk A; Wróbel T; Wachowiak J; Kałwak K; Główka F
    Eur J Pharm Sci; 2018 Jul; 120():1-9. PubMed ID: 29705215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation.
    Danielak D; Twardosz J; Kasprzyk A; Wachowiak J; Kałwak K; Główka F
    Eur J Clin Pharmacol; 2018 Jan; 74(1):79-89. PubMed ID: 28975382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT.
    Główka F; Kasprzyk A; Romański M; Wróbel T; Wachowiak J; Szpecht D; Kałwak K; Wiela-Hojeńska A; Dziatkiewicz P; Teżyk A; Żaba C
    Eur J Pharm Sci; 2015 Feb; 68():87-93. PubMed ID: 25527118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treosulfan-Based Conditioning Regimen in Haematopoietic Stem Cell Transplantation with TCRαβ/CD19 Depletion in Nijmegen Breakage Syndrome.
    Laberko A; Sultanova E; Gutovskaya E; Radygina S; Deripapa E; Kantulaeva A; Trakhtman P; Brilliantova V; Starichkova J; Shcherbina A; Maschan M; Maschan A; Balashov D
    J Clin Immunol; 2020 Aug; 40(6):861-871. PubMed ID: 32602054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.
    Główka FK; Romański M; Wachowiak J
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1275-95. PubMed ID: 20836619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
    Kletzel M; Jacobsohn D; Duerst R
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen.
    Korula A; Pn N; Devasia A; Lakshmi KM; Abraham A; Sindhuvi E; George B; Srivastava A; Mathews V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):103-108. PubMed ID: 29032269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial.
    Chiesa R; Standing JF; Winter R; Nademi Z; Chu J; Pinner D; Kloprogge F; McLellen S; Amrolia PJ; Rao K; Lucchini G; Silva J; Ciocarlie O; Lazareva A; Gennery AR; Doncheva B; Cant AJ; Hambleton S; Flood T; Rogerson E; Devine K; Prunty H; Heales S; Veys P; Slatter M
    Clin Pharmacol Ther; 2020 Aug; 108(2):264-273. PubMed ID: 31701524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
    Huttunen P; Taskinen M; Vettenranta K
    Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
    van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
    Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
    Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
    Wall DA; Chan KW; Nieder ML; Hayashi RJ; Yeager AM; Kadota R; Przepiorka D; Mezzi K; Kletzel M;
    Pediatr Blood Cancer; 2010 Feb; 54(2):291-8. PubMed ID: 19743300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
    Bernardo ME; Zecca M; Piras E; Vacca A; Giorgiani G; Cugno C; Caocci G; Comoli P; Mastronuzzi A; Merli P; La Nasa G; Locatelli F
    Br J Haematol; 2008 Nov; 143(4):548-51. PubMed ID: 18986389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
    Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
    Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major.
    Hussein AA; Al-Zaben A; Ghatasheh L; Natsheh A; Hammada T; Abdel-Rahman F; Abu-Jazar H; Sharma S; Najjar R; Frangoul H
    Pediatr Blood Cancer; 2013 Aug; 60(8):1345-9. PubMed ID: 23424175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
    Lüftinger R; Zubarovskaya N; Galimard JE; Cseh A; Salzer E; Locatelli F; Algeri M; Yesilipek A; de la Fuente J; Isgrò A; Alseraihy A; Angelucci E; Smiers FJ; La La Nasa G; Zecca M; Fisgin T; Unal E; Kleinschmidt K; Peters C; Lankester A; Corbacioglu S;
    Ann Hematol; 2022 Mar; 101(3):655-665. PubMed ID: 34999929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.
    Tesfaye H; Branova R; Klapkova E; Prusa R; Janeckova D; Riha P; Sedlacek P; Keslova P; Malis J
    Ann Transplant; 2014 May; 19():214-24. PubMed ID: 24811685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.
    van der Stoep MYEC; Bertaina A; Ten Brink MH; Bredius RG; Smiers FJ; Wanders DCM; Moes DJAR; Locatelli F; Guchelaar HJ; Zwaveling J; Lankester AC
    Br J Haematol; 2017 Dec; 179(5):772-780. PubMed ID: 29048102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.